Tag: <span>HUMIRA</span>

Home / HUMIRA
AbbVie and Eisai Announce an approval for additional indication of HUMIRA
Post

AbbVie and Eisai Announce an approval for additional indication of HUMIRA

A fully Human Anti-TNFalpha Monoclonal Antibody, for the treatment of pyoderma gangrenosum for the first time in the world. AbbVie GK and Eisai Co., Ltd. today announced an approval of additional indication of HUMIRA (generic name: adalimumab [recombinant], hereafter “HUMIRA”), a fully human anti-TNFalpha monoclonal antibody, for the treatment of pyoderma gangrenosum (hereafter “PG”). HUMIRA...